Expert Interview
Second View: Discussing Arvinas' Phase 1 trial for PROTACT ARV-102, an oral medication demonstrating blood-brain barrier penetration, and central and peripheral LRRK2 degradation.
Ticker(s): ARVNInstitution: Icahn School of Medicine at Mount Sinai
- Manages 20 patients per week with Parkinson's disease
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
